Benralizumab - administered by injection - is a monoclonal antibody that targets specific white blood cells, called ...

First breakthrough in treating asthma attacks and COPD in 50 years hailed as a ‘game-changer’ by doctors - Benralizumab is a ...

In the course of the ALS development program, however, dexpramipexole was observed to produce a significant and targeted depletion of eosinophils in the blood of ALS patients 4. Eosinophils are ...

A new way of treating serious asthma and chronic obstructive pulmonary disease (COPD) attacks could be a "game-changer" ...

Scientists have found a new treatment for people with asthma and chronic obstructive pulmonary disease (COPD) that may be more effective than current options. Over the past 50 years, treatment options ...

Opens in a new tab or window The investigational monoclonal antibody cendakimab significantly improved symptoms and reduced esophageal eosinophils in patients with eosinophilic esophagitis at 24 ...

Benralizumab, a monoclonal antibody, is the first breakthrough in asthma and COPD flare-up treatment in 50 years. Targeting ...

Scientists say this is the first new way of treating the attacks in 50 years despite 3.8 million deaths across the world ...

This disruption leads to a boost in eosinophils in the lungs. Eosinophils are immune cells that hinder the function of other cells responsible for clearing pathogens from the lungs. In a mouse model ...

In hospitalized patients, eosinophil levels positively correlated with antibiotic use, systemic inflammation, and worsened ...

Amali Samarasinghe, PhD, associate professor in the Department of Pediatrics at UT Health Science Center, describes herself as an aficionada of the alternative hypothesis. “I have a passion to uncover ...